TY  - JOUR

T1  - EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer

JO  - Annals of Oncology

UR  - http://dx.doi.org/10.1093/annonc/mdu269

PY  - 2014/07/23

AU  - Heymach JV

AU  - Lockwood SJ

AU  - Herbst RS

AU  - Johnson BE

AU  - Ryan AJ

ED  - 

DO  - DOI: 10.1093/annonc/mdu269

PB  - Elsevier BV

VL  - 25

IS  - 10

SP  - 1941

EP  - 1948

Y2  - 2024/12/22

ER  -